| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Martyn Wood, Charlie Reavil. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert opinion on investigational drugs. vol 16. issue 6. 2007-07-20. PMID:17501690. |
aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. |
2007-07-20 |
2023-08-12 |
Not clear |
| Carl Salzman, Jennifer Rosenberg, James J Feldma. Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole. The Journal of clinical psychiatry. vol 68. issue 6. 2007-07-19. PMID:17592928. |
schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole. |
2007-07-19 |
2023-08-12 |
Not clear |
| Giovan B Cassano, Andrea Fagiolini, Lorenzo Lattanzi, Palmiero Monteleone, Cinzia Niolu, Emilio Sacchetti, Alberto Siracusano, Antonio Vit. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clinical drug investigation. vol 27. issue 1. 2007-07-17. PMID:17177576. |
aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in italy. |
2007-07-17 |
2023-08-12 |
Not clear |
| Giovan B Cassano, Andrea Fagiolini, Lorenzo Lattanzi, Palmiero Monteleone, Cinzia Niolu, Emilio Sacchetti, Alberto Siracusano, Antonio Vit. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clinical drug investigation. vol 27. issue 1. 2007-07-17. PMID:17177576. |
aripiprazole thus provides clinicians with another treatment option, and in october 2005, schizophrenia experts participated in an expert consensus meeting that aimed to agree on a set of guidelines for best-practice use of aripiprazole in the acute and long-term management of schizophrenia in italy. |
2007-07-17 |
2023-08-12 |
Not clear |
| Leslie Citrome, Jean-Paul Macher, Daniel E Salazar, Suresh Mallikaarjun, David W Boulto. Pharmacokinetics of aripiprazole and concomitant carbamazepine. Journal of clinical psychopharmacology. vol 27. issue 3. 2007-07-13. PMID:17502775. |
the objective of this study was to assess the pharmacokinetics of aripiprazole when coadministered with carbamazepine using an open-label sequential treatment design in patients with schizophrenia or schizoaffective disorder. |
2007-07-13 |
2023-08-12 |
human |
| Leslie Citrome, Jean-Paul Macher, Daniel E Salazar, Suresh Mallikaarjun, David W Boulto. Pharmacokinetics of aripiprazole and concomitant carbamazepine. Journal of clinical psychopharmacology. vol 27. issue 3. 2007-07-13. PMID:17502775. |
thus, therapeutic doses of carbamazepine had significant effects on the pharmacokinetics of aripiprazole in patients with schizophrenia or schizoaffective disorder. |
2007-07-13 |
2023-08-12 |
human |
| Bradley Freeman, Woodburne Levy, Jack M Gorma. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of psychiatric practice. vol 13. issue 2. 2007-05-30. PMID:17414690. |
successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. |
2007-05-30 |
2023-08-12 |
Not clear |
| Stephen R Marder, Britt West, Gina S Lau, Joseph A Pultz, Andrei Pikalov, Ronald N Marcus, Rolando Gutierrez-Esteinou, David T Crandal. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. The Journal of clinical psychiatry. vol 68. issue 5. 2007-05-21. PMID:17503974. |
aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. |
2007-05-21 |
2023-08-12 |
Not clear |
| Stephen R Marder, Britt West, Gina S Lau, Joseph A Pultz, Andrei Pikalov, Ronald N Marcus, Rolando Gutierrez-Esteinou, David T Crandal. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. The Journal of clinical psychiatry. vol 68. issue 5. 2007-05-21. PMID:17503974. |
in order to determine whether baseline agitation level influences treatment response, the effects of oral aripiprazole in acute patients with schizophrenia experiencing either higher or lower levels of agitation were examined. |
2007-05-21 |
2023-08-12 |
Not clear |
| Pierre Thoma. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17 Suppl 2. 2007-05-14. PMID:17336766. |
twenty-six weeks of aripiprazole treatment, assessed in 284 patients in the schizophrenia trial of aripiprazole (star) showed that aripiprazole had similar discontinuation rates to the atypical antipsychotics standard of care. |
2007-05-14 |
2023-08-12 |
Not clear |
| Andrea Fagiolini, Arianna Goracc. The long term--maximising potential for rehabilitation in patients with schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17 Suppl 2. 2007-05-14. PMID:17336767. |
the schizophrenia trial of aripiprazole (star), in which patients were randomised to receive 26 weeks of the atypical antipsychotic, aripiprazole (n=284) or standard of care medication (n=271) showed that aripiprazole demonstrated significantly better effectiveness in terms of investigator assessment questionnaire (iaq) total score. |
2007-05-14 |
2023-08-12 |
Not clear |
| Charalampos I Mitsonis, Nikolaos P Dimopoulos, Panagiotis A Mitropoulos, Evangelia G Kararizou, Alexandra N Katsa, Fivos E Tsakiris, Maria Nefeli E Katsano. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17092620. |
aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. |
2007-04-24 |
2023-08-12 |
Not clear |
| Charalampos I Mitsonis, Nikolaos P Dimopoulos, Panagiotis A Mitropoulos, Evangelia G Kararizou, Alexandra N Katsa, Fivos E Tsakiris, Maria Nefeli E Katsano. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17092620. |
the aim of this study was to investigate whether augmentation of clozapine with aripiprazole improves clinically significant residual symptoms in stabilized outpatients with chronic schizophrenia. |
2007-04-24 |
2023-08-12 |
Not clear |
| Raisa Andrezina, Richard C Josiassen, Ronald N Marcus, Dan A Oren, George Manos, Elyse Stock, William H Carson, Taro Iwamot. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology. vol 188. issue 3. 2007-03-13. PMID:16953381. |
intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. |
2007-03-13 |
2023-08-12 |
Not clear |
| Raisa Andrezina, Richard C Josiassen, Ronald N Marcus, Dan A Oren, George Manos, Elyse Stock, William H Carson, Taro Iwamot. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology. vol 188. issue 3. 2007-03-13. PMID:16953381. |
this double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (im) aripiprazole and im haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder. |
2007-03-13 |
2023-08-12 |
Not clear |
| John M Kane, Herbert Y Meltzer, William H Carson, Robert D McQuade, Ronald N Marcus, Raymond Sanche. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. The Journal of clinical psychiatry. vol 68. issue 2. 2007-03-09. PMID:17335319. |
aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. |
2007-03-09 |
2023-08-12 |
Not clear |
| John M Kane, Herbert Y Meltzer, William H Carson, Robert D McQuade, Ronald N Marcus, Raymond Sanche. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. The Journal of clinical psychiatry. vol 68. issue 2. 2007-03-09. PMID:17335319. |
this multicenter, double-blind, randomized study compared the efficacy and safety of aripiprazole and perphenazine in treatment-resistant patients with schizophrenia. |
2007-03-09 |
2023-08-12 |
Not clear |
| Hung-Yu Chan, Wei-Wen Lin, Shih-Ku Lin, Tzung-Jeng Hwang, Tung-Ping T Su, Shu-Chuan Chiang, Hai-Gwo Hw. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. The Journal of clinical psychiatry. vol 68. issue 1. 2007-02-20. PMID:17284127. |
efficacy and safety of aripiprazole in the acute treatment of schizophrenia in chinese patients with risperidone as an active control: a randomized trial. |
2007-02-20 |
2023-08-12 |
Not clear |
| Hung-Yu Chan, Wei-Wen Lin, Shih-Ku Lin, Tzung-Jeng Hwang, Tung-Ping T Su, Shu-Chuan Chiang, Hai-Gwo Hw. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. The Journal of clinical psychiatry. vol 68. issue 1. 2007-02-20. PMID:17284127. |
this study aimed to investigate the efficacy, safety, and tolerability of aripiprazole in chinese patients with acute schizophrenia or schizoaffective disorder. |
2007-02-20 |
2023-08-12 |
Not clear |
| Professor Ann M Mortime. Review: aripiprazole for schizophrenia--more high quality research required. Evidence-based mental health. vol 10. issue 1. 2007-02-12. PMID:17255383. |
review: aripiprazole for schizophrenia--more high quality research required. |
2007-02-12 |
2023-08-12 |
Not clear |